Table 1 Structural analogs generated during the successive engineering
From: Gene conversion-associated successive engineering of modular polyketide synthases
Strain | Compound | Production Yielda | Construction method |
|---|---|---|---|
Wild-type (S.cinnamoneus) | 1b | ~50 mg/L | N/Ac |
1b | ~2 mg/L | ||
1c | ~1 mg/L | ||
2 | ~10 mg/L | ||
ΔcmmB | 3 | ~50 mg/L | cmmB in-frame deletion mutant2 |
4 | ~10 mg/L | ||
WT+mgmO | 5 | ~10 mg/L | mgmO gene integrated strain of WT |
6 | ~2 mg/L | ||
ΔcmmB+mgmO | 7 | ~10 mg/L | mgmO gene integrated strain of ΔcmmB mutant |
8 | ~2 mg/L | ||
S1 | 9 | ~50 mg/L | Cmm-AT1 replacement mutant with Cmm-AT4 in WT |
10 | ~15 mg/L | ||
S2 | 11 | ~30 mg/L | Cmm-AT4 replacement mutant with Mgm-AT5 in WT |
12 | ~7 mg/L | ||
S3 | 13a | ~5 mg/L | Cmm-AT5 replacement mutant with Mgm-AT5 in WT |
13b | ~0.5 mg/L | ||
14a | ~3 mg/L | ||
15a | ~2 mg/L | ||
S4 | 16 | ~15 mg/L | Cmm-AT4 replacement mutant with Mgm-AT5 in S3 |
17 | ~3 mg/L | ||
S5 | 18a | ~2 mg/L | Cmm-AT5 replacement mutant with Mgm-AT5 in S4 |
18b | ~1.5 mg/L | ||
18c | ~0.5 mg/L | ||
19a | ~4 mg/L | ||
19b | ~5 mg/L | ||
19c | ~5 mg/L | ||
S5-mgmKS5 | 18a | ~1.5 mg/L | Cmm-KS5 replacement mutant with Mgm-KS5 in S5 |
18b | ~4 mg/L | ||
18c | ~4 mg/L | ||
S6 | 20 | Trace | cmmB in-frame deletion mutant in S5-mgmKS5 |
S7 | 21 | ~0.5 mg/L | CCR-HCD- mgmO co-overexpression in mutant S6 |
